Cite
HARVARD Citation
Ghobrial, I. et al. (n.d.). Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. American journal of hematology. 94 (11), pp. 1244-1253. [Online].